CA19.9 and XXXX in transitional cell @entity150 : serological and immunohistochemical findings.

@entity1 @entity8214 @entity1803 @entity1494 @entity5 @entity344 @entity787 @entity150
BACKGROUND: Reliable blood and urine markers for transitional cell @entity150 ( @entity8214 ) do not currently exist. The aim of this prospective study was the serological and immunohistochemical evaluation of CA19.9 and @entity787 in @entity8214 and to assess the correlation with different @entity8214 stages. @entity1 AND METHODS: CA19.9 and @entity787 levels were prospectively determined in samples from 231 @entity1 with @entity8214 suspected @entity1494 , before transurethral @entity5 resection. Additionally, these serum parameters were determined in 11 @entity1 with initial metastatic @entity8214 . Immunohistochemical analysis on CA19.9 and @entity787 was performed in 83 @entity1 . RESULTS: Neither CA19.9 nor @entity787 levels were significantly elevated in @entity8214 @entity1 . @entity1 with muscle-invasive @entity8214 showed significantly higher levels of @entity787 (p = 0.008) and CA19.9 (p<0.001) compared to those with superficial @entity8214 . Significantly higher levels were also evident with increasing grade of @entity5 . Metastatic @entity8214 showed significantly elevated CA19.9 levels compared to muscle invasive @entity8214 as well as locally advanced ( @entity1803 /pT4/pN+) compared to localized @entity8214 (pT2/pN0). Immunohistochemical staining revealed a strong correlation between CA19.9 serum levels and staining intensity. CONCLUSION: @entity787 and CA19.9 are not useful markers in primary diagnosis of @entity8214 . However, in instances of elevated @entity787 and CA19.9 levels where @entity344 has been excluded, evidence of @entity8214 should be sought. If elevated @entity787 and CA19.9 are present in @entity8214 , serum levels correlate with @entity5 invasion and grade of @entity5 .
